At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ERNA Eterna Therapeutics Inc.
Trading 10-14 10:05:32 EDT
2.11
-0.10
-4.52%
High2.20Low2.10Vol3.57K
Open2.20D1 Closing2.21Amplitude4.52%
Mkt Cap3.44MTradable Cap2.56MTotal Shares1.63M
T/O7.62KT/O Rate0.29%Tradable Shares1.22M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Ernexa Therapeutics Joins Virtual Investor Closing Bell Series Webcast
Reuters  ·  10-13 04:06
Ernexa Therapeutics Joins Virtual Investor Closing Bell Series Webcast
Ernexa Says ERNA-101 Preclinical Data Win Flash Talk Slot at Nature-MD Anderson Cancer Meeting
Reuters  ·  10-06
Ernexa Says ERNA-101 Preclinical Data Win Flash Talk Slot at Nature-MD Anderson Cancer Meeting
Ernexa Therapeutics Appoints Robert J. Spiegel to Board of Directors
Reuters  ·  10-01
Ernexa Therapeutics Appoints Robert J. Spiegel to Board of Directors
Ernexa Therapeutics CEO Corner Highlights Appointment of DR. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances Erna-101 Toward the Clinic
THOMSON REUTERS  ·  10-01
Ernexa Therapeutics CEO Corner Highlights Appointment of DR. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances Erna-101 Toward the Clinic
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
GlobeNewswire  ·  10-01
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
Ernexa Therapeutics announces ‘highly encouraging’ results on ERNA-101
TIPRANKS  ·  09-30
Ernexa Therapeutics announces ‘highly encouraging’ results on ERNA-101
Ernexa Targets Q4 2026 IND Filing for First-in-Human ERNA-101 Trial in Platinum-Resistant Ovarian Cancer
Reuters  ·  09-30
Ernexa Targets Q4 2026 IND Filing for First-in-Human ERNA-101 Trial in Platinum-Resistant Ovarian Cancer
Ernexa Therapeutics - no Teratoma Formation Observed in Erna-101-Treated Animals Through Six-Month Tumorigenicity Phase
THOMSON REUTERS  ·  09-30
Ernexa Therapeutics - no Teratoma Formation Observed in Erna-101-Treated Animals Through Six-Month Tumorigenicity Phase
Ernexa Therapeutics Reports Compelling Erna-101 Safety Results Across Three Critical Ind-Enabling Studies, Advancing Toward Planned Q4 2026 Ind
THOMSON REUTERS  ·  09-30
Ernexa Therapeutics Reports Compelling Erna-101 Safety Results Across Three Critical Ind-Enabling Studies, Advancing Toward Planned Q4 2026 Ind
Ernexa Therapeutics - Biodistribution Study Shows no Significant Erna-101 Signal in Tumor-Free Animals or Non-Tumor Tissues
THOMSON REUTERS  ·  09-30
Ernexa Therapeutics - Biodistribution Study Shows no Significant Erna-101 Signal in Tumor-Free Animals or Non-Tumor Tissues
Ernexa Therapeutics - Repeat-Dose Glp Toxicology Study Shows no Erna-101-Related Adverse Findings
THOMSON REUTERS  ·  09-30
Ernexa Therapeutics - Repeat-Dose Glp Toxicology Study Shows no Erna-101-Related Adverse Findings
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
GlobeNewswire  ·  09-30
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Ernexa Therapeutics selected for Emerging Track at 2026 Cell, Gene meeting
TIPRANKS  ·  09-29
Ernexa Therapeutics selected for Emerging Track at 2026 Cell, Gene meeting
Ernexa Therapeutics CEO to Present at Cell & Gene Meeting on the Mesa Emerging Track
Reuters  ·  09-29
Ernexa Therapeutics CEO to Present at Cell & Gene Meeting on the Mesa Emerging Track
Ernexa Therapeutics Director Robert J. Spiegel Files Initial Beneficial Ownership Statement
Reuters  ·  09-23
Ernexa Therapeutics Director Robert J. Spiegel Files Initial Beneficial Ownership Statement
Ernexa Therapeutics Appoints Robert J. Spiegel to Board of Directors
Reuters  ·  09-17
Ernexa Therapeutics Appoints Robert J. Spiegel to Board of Directors
Ernexa Therapeutics - Intends to Broaden Oncology Program and Advance Next-Generation Imsc Candidates
THOMSON REUTERS  ·  09-15
Ernexa Therapeutics - Intends to Broaden Oncology Program and Advance Next-Generation Imsc Candidates
Ernexa Therapeutics - to Concentrate Near-Term Resources on Erna-101 and Broaden Oncology Strategy
THOMSON REUTERS  ·  09-15
Ernexa Therapeutics - to Concentrate Near-Term Resources on Erna-101 and Broaden Oncology Strategy
Ernexa Therapeutics Reports Positive Disease Modifying Erna-201 Preclinical Data, Reinforcing Imsc Platform as Company Accelerates Oncology Strategy and Erna-101 Toward First-in-Human Dosing
THOMSON REUTERS  ·  09-15
Ernexa Therapeutics Reports Positive Disease Modifying Erna-201 Preclinical Data, Reinforcing Imsc Platform as Company Accelerates Oncology Strategy and Erna-101 Toward First-in-Human Dosing
Ernexa Therapeutics - to Advance Erna-101 Toward Ind Submission for Platinum-Resistant Ovarian Cancer
THOMSON REUTERS  ·  09-15
Ernexa Therapeutics - to Advance Erna-101 Toward Ind Submission for Platinum-Resistant Ovarian Cancer

Introduction

Company Name.
Eterna Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Issue price:
--